ENDONOVO THERAPEUTICS, INC. (ENDV)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2022, ENDONOVO THERAPEUTICS, INC. reported revenue of $135.4K, up 85.2% from the prior year. The company ran a net loss, with a net margin of -13649.2% and a gross margin of 92.6%. It held $1.28M in total assets against $33.46M in total liabilities.
Key ratios (FY2022)
92.6%
Gross margin
-2411.7%
Operating margin
-13649.2%
Net margin
+85.2%
Revenue growth (YoY)
| Metric (FY) | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $135.4K | $73.1K | $165.8K | $310.2K | $83.3K | — | — | — | — | — |
| Cost of Revenue | $10.0K | $15.0K | $65.4K | $93.4K | $12.9K | — | — | — | — | — |
| Gross Profit | $125.4K | $58.1K | $100.4K | $216.8K | $70.3K | — | — | $2.1K | $8.7K | $8.9K |
| Operating Income | -$3.26M | -$2.23M | -$2.91M | -$3.81M | -$4.16M | -$4.60M | -$5.41M | -$2.56M | -$2.19M | -$2.43M |
| Net Income | -$18.47M | -$3.10M | -$395.6K | -$17.31M | -$6.44M | -$10.81M | -$5.32M | -$6.77M | -$959.5K | -$2.89M |
| EPS (Diluted) | $-0.13 | $-0.05 | — | — | — | — | — | — | — | — |
| Total Assets | $1.28M | $2.01M | $2.61M | $3.27M | $4.24M | $4.61M | $318.7K | $409.4K | $45.6K | $73.6K |
| Total Liabilities | $33.46M | $17.78M | $16.98M | $23.78M | $15.63M | $14.16M | $8.88M | $9.69M | $4.74M | $4.21M |
| Shareholders' Equity | -$32.18M | -$15.77M | -$14.37M | -$20.50M | -$11.39M | -$9.55M | -$8.56M | -$9.28M | -$4.69M | -$4.13M |
| Cash & Equivalents | — | $85.9K | $13.4K | $18.9K | $379.2K | $90.2K | $55.5K | $41.5K | $988 | $3.3K |
| Operating Cash Flow | -$678.8K | -$986.6K | -$741.6K | -$2.54M | -$2.88M | -$2.99M | -$2.46M | -$1.02M | -$909.3K | -$257.4K |
| Capital Expenditures | — | — | — | $2.6K | $9.0K | — | — | $3.8K | $0 | — |
| Shares Outstanding | 213.23M | 74.50M | 24.54M | 1.19M | 431.1K | 316.95M | 134.34M | 104.80M | 81.43M | 832.2K |